Investor Presentaiton
Clinical Pipeline Milestones: Expected in 2024
2024H1
HLX10
MSI-H solid tumors
HLX10
ESCC²
HLX10
ES-SCLC3
Late-line (Hong Kong
SAR, Macao SAR)
1L (Macao
SAR)
1L (US, Vietnam, UK,
NDA/BLA/MAA
Submission
HLX14
PMOP1
(EU & US)
HLX10
ES-SCLC3
1L (the Philippines, Hong
Kong SAR, Macao SAR)
HLX10
sqNSCLC4
1L (Indonesia,
Macao SAR)
HLX10+HLX04
MCRC6
1L (POC)
HLX22+HLX02
Key Clinical
GC7
1L (POC)
Data Readouts
1.
Postmenopausal osteoporosis
23
2.
Esophageal squamous cell carcinoma 5.
3.
Extensive stage small cell lung
24
cancer
4597
4. Squamous non-small cell lung cancer 8.
Age-related macular degeneration
9.
6.
7.
Metastatic colorectal cancer
Gastric cancer
India)
HLX04-0
Wet AMD5
1L (China)
HLX22+HLX02
GC
1L (POC)
2024H2
HLX10
sqNSCLC4
1L (India)
HLX11
Breast cancer
Neoadjuvant
therapy (US, China)
HLX10
MSI-H solid tumors
Late-line (India)
HLX14
PMOP1
(US)
HLX04-O
Wet AMD
1L (China Pivotal)
HLX10
ESCC2
1L (India)
HLX11
Breast cancer
Neoadjuvant therapy (Pivotal)
HLX10+HLX04
HLX07+HLX10
mCRC6
NPC8
1L (POC)
1L (China PoC)
HLX14
PMOP1
(Pivotal)
HLX10
nsNSCLC⁹
1L (Pivotal)
HLX10
ES-SCLC3
1L (Bridging)
Nasopharyngeal carcinoma
Non-squamous non-small cell lung
© 2024 Henlius.
cancer
The Company's internal planning time is subject to the actual
situation, and shareholders and potential investors of the Company
are advised to exercise caution when trading the Company's shares.
Innovative mAb
mAb biosimilar
2 HenliusView entire presentation